Broader off-label coverage under Part D
Sens. Dianne Feinstein, D-Calif., and Sam Brownback, R-Kan., urge broader access to off-label indications under Medicare Part D in a May 22 letter to the Senate Finance Committee. The senators, who co-chair the Senate Cancer Coalition, urge that Medicare legislation being drafted by the committee include a provision allowing Part D plans to consider the "full range" of evidence in making off-label coverage decisions and bring reimbursement standards for Part D "into line with coverage standards used under Medicare Part B and by commercial insurers." CMS is currently reviewing appropriate compendia for off-label coverage under Part B (1"The Pink Sheet," April 14, 2008, p. 15)
You may also be interested in...
CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.